**Clinical Risk Assessment and Management Plan**

|  |  |  |  |
| --- | --- | --- | --- |
| **Study Acronym / Short Title** |  | **R&D Number** |  |
| **Protocol Version** |  | **Date** |  |

**When completing below please consider MHRA guidance regarding COVID19:** [**Guidance Managing clinical trials during Coronavirus (COVID-19)**](https://www.gov.uk/guidance/managing-clinical-trials-during-coronavirus-covid-19)

|  |  |
| --- | --- |
| Does your risks identified containing the following: | Yes/No |
| **A direct participant safety issue, especially if there is the potential to impact other trials** |  |
| **A medicines supply issue** |  |

Please liaise with you RGIT Monitor to confirm any updates to trial monitoring. Any updates should be documented in the risk assessment.

|  |  |
| --- | --- |
|  | |
| **Risk Identified** | **Mitigation Plan** |
|  |  |
|  |  |
|  |  |
|  |  |
|  |  |

|  |  |  |  |
| --- | --- | --- | --- |
|  | **Print Name and Role** | **Signature** | **Date** |
| *Sponsor:* |  |  |  |
| *Chief Investigator* |  |  |  |